BRAINSTORM CELL THERAPEUTICS INC. Share-based Payment Arrangement, Expense
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Share-based Payment Arrangement, Expense of $133.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-05-15
- BRAINSTORM CELL THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $133.00K, a 81.45% decline year-over-year.
- BRAINSTORM CELL THERAPEUTICS INC. share-based payment arrangement, expense for the quarter ending 2025-03-31 was $717.00K.
| Period end | Share-based Payment Arrangement, Expense 3 month |
|---|---|
| 2026-03-31 | $133.00K 10-Q · filed 2026-05-15 |
| 2025-03-31 | $717.00K 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |